Genus PLC
12 September 2007

For Immediate Release 12 September 2007

Genus Plc

('Genus' or 'the Company')

Statement regarding Foot & Mouth Disease

Genus, the leading global multi species genetics company makes the following statement in relation to the instance of foot and mouth disease that has been reported today.

In line with the Company's announcement on 6 August 2007 Genus confirms the instance of foot and mouth disease will have no measurable impact upon its business.

The comparatively harsh foot and mouth outbreak in 2001 had no adverse impact on the business. Since then, Genus has developed both geographically and in species. Currently, only 14% of company turnover is in GB animal related business.

All of Genus' GB breeding stock facilities are located far from the source of the outbreak. Nevertheless, we have further enhanced our already high bio-security procedures.

The Board will keep the situation under constant review and will make a further announcement if the situation changes from that described above.

For further information, please contact:

Genus Plc Tel: +44 (0)1256 345 971
Richard Wood, Chief Executive

Buchanan Communications Tel: +44 (0)20 7466 5000
Charles Ryland / Suzanne Brocks

Notes to Editors:

Genus is a world leader in applying science to animal breeding. The unique combination of quantitative genetics and biotechnology used by Genus is applicable across all livestock species and enables farmers and producers to produce higher quality and healthier non-GMO food products. Genus' current products and services enable producers and farmers to enhance milk and meat quality and improve efficiency through the application of genetic selection.

Genus' business units, ABS (dairy and beef cattle) and PIC (pigs) sell breeding animals and semen to customers who produce offspring which yield greater production efficiency, milk and meat quality for the global dairy and meat supply chain. Genus' competitive differentiation lies in its ownership and control of its proprietary lines of breeding animals, its biotechnology used to improve them and its global production and distribution network.

Genus' technology and products add value throughout the global supply chain of farmers, breeders, processors, distributors, retailers and consumers.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries on five continents, with laboratories located in Madison, USA.

This information is provided by RNS
The company news service from the London Stock Exchange